Cline Scientific AB Series B
Cline Scientific AB (publ), a life science company, develops cancer diagnostics and stem cell therapies in Sweden. The company's clinical-stage projects include StemCART, a stem cell therapy for joint repair; and CellRACE, a cancer diagnostic to predict metastasis. It also develops nanotechnology based products for work within Life Sciences. The company has collaboration with Sahlgrenska that dev… Read more
Cline Scientific AB Series B (CLINE-B) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2023: 0.048x
Based on the latest financial reports, Cline Scientific AB Series B (CLINE-B) has a cash flow conversion efficiency ratio of 0.048x as of December 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr968.36K) by net assets (Skr20.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cline Scientific AB Series B - Cash Flow Conversion Efficiency Trend (2012–2023)
This chart illustrates how Cline Scientific AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cline Scientific AB Series B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cline Scientific AB Series B ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Elcora Advanced Materials Corp
PINK:ECORF
|
0.029x |
|
MURATA MFG
MU:MUR1
|
0.062x |
|
Great Dane Globale Aktier
CO:GDIGA
|
N/A |
|
Great Dane INDEX+
CO:GDIIND
|
N/A |
|
TIETO CORPORATION
MU:TTEB
|
N/A |
|
Selected Investments Equities
CO:SIIEQT
|
N/A |
|
WORLD FUEL SERVICES
BE:WFK
|
-0.019x |
|
Stifel Financial Corporation 5.20% Senior Notes due 2047
NYSE:SFB
|
-0.072x |
Annual Cash Flow Conversion Efficiency for Cline Scientific AB Series B (2012–2023)
The table below shows the annual cash flow conversion efficiency of Cline Scientific AB Series B from 2012 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | Skr20.10 Million | Skr-1.73 Million | -0.086x | +42.82% |
| 2022-12-31 | Skr17.46 Million | Skr-2.62 Million | -0.150x | -14.85% |
| 2021-12-31 | Skr16.74 Million | Skr-2.19 Million | -0.131x | +38.66% |
| 2020-12-31 | Skr10.12 Million | Skr-2.16 Million | -0.213x | +72.30% |
| 2019-12-31 | Skr2.52 Million | Skr-1.94 Million | -0.770x | +1.16% |
| 2018-12-31 | Skr4.62 Million | Skr-3.60 Million | -0.779x | +46.15% |
| 2017-12-31 | Skr1.58 Million | Skr-2.29 Million | -1.446x | -146.75% |
| 2016-12-31 | Skr4.91 Million | Skr-2.88 Million | -0.586x | -69.03% |
| 2015-12-31 | Skr7.75 Million | Skr-2.69 Million | -0.347x | -137.99% |
| 2013-12-31 | Skr292.49K | Skr267.00K | 0.913x | +101.52% |
| 2012-12-31 | Skr6.00K | Skr-361.41K | -60.235x | -- |